Precision antibody-based synergistic drug combinations for refractory triple-negative breast cancer
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2110058
- Recipient
-
The General Hospital Corporation UEI FLJ7DQKLL226 Part of Partners Healthcare System Incorporated
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $781,530
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Boston, MA 02114, USA
Award details come from USAspending.gov.
About this award
The Department of the Army Medical Command awarded a $781,530 Project Grant to the Massachusetts General Hospital through the Military Medical Research and Development program. The grant will fund research from February 2021 to January 2024 to develop precision antibody-based synergistic drug combinations for refractory triple-negative breast cancer.
The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of improving military and public health outcomes. This award will allow Massachusetts General Hospital researchers to investigate medical solutions for difficult-to-treat breast cancers, advancing the program's mission to transform healthcare through innovative research.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $781,530 |
Quick answers
Who received award W81XWH2110058?
W81XWH2110058 was awarded to The General Hospital Corporation by Medical Command (Department of the Army) on February 1, 2021.
How much is award W81XWH2110058 worth?
$781,530 has been obligated on W81XWH2110058.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award